Clinical trials: Dermatitis Eczema
Dermatitis, Atopic
Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis
The purpose of this study is to determine whether AN2898 and AN2728 ointments are safe and effective treatments for mild-to-moderate atopic dermatitis (AD).
- Trial name
- NCT01301508
- Testing
- AN2728 ointment, 2%, AN2898 ointment, 1%, AN2898 ointment vehicle
- Where
- 13 sites in Australia
- Volunteers
- 46 people
- Sponsor
- Pfizer
Dermatitis, Atopic
Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis
this study is to evaluate the potential of DSXS to suppress HPA axis function in patients with moderate to severe atopic dermatitis.
- Trial name
- NCT02595008
- Testing
- DSXS
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Mild to Moderate Atopic Dermatitis
Evaluation of the Effect of the Product RV4660C CY0203 on Clinical, Biometrological and Biological Parameters in Adults With Mild to Moderate Atopic Dermatitis, an Exploratory Study
In this exploratory study, we assessed the efficacy of a cosmetic product in adults suffering from mild to moderate atopic dermatitis. This exploratory study has been conducted as a monocentric non randomized study.
- Trial name
- NCT07166497
- Testing
- Cosmetic product RV4660C CY0203
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Dermatitis Atopic
A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants
The purpose of this study is to evaluate the skin irritation potential of PF-07038124 ointment and vehicle (placebo) in Part A following multiple-doses applied topically to healthy participants.
- Trial name
- NCT04135560
- Testing
- PF-07038124 and Vehicle, PF-07038124 or vehicle
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Pfizer
Atopic Dermatitis
A Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis.
The main purpose of this phase 2 study was to assess the efficacy and safety of CMK389 in patients with atopic dermatitis.
- Trial name
- NCT04836858
- Testing
- CMK389
- Where
- 18 sites in Czechia, France and 4 more
- Volunteers
- 71 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Hand Eczema (CHE)
Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement…
- Trial name
- TRuE-CHE2 (NCT05233410)
- Testing
- Ruxolitinib cream, Vehicle
- Where
- 39 sites in United States, Bulgaria and 5 more
- Sponsor
- Incyte Corporation
Atopic Dermatitis
Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
To assess the efficacy of multiple dupilumab dose-regimens, compared to placebo, in adult participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT01859988
- Testing
- Dupilumab
- Where
- 84 sites in United States, Canada and 5 more
- Volunteers
- 380 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis (AD)
Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis
The goal of this clinical trial is to learn if drug LT-002-158 works to treat moderate-to-severe atopic dermatitis in adults. It will also learn about the safety of drug LT-002-158.
- Trial name
- NCT07895615
- Testing
- LT-002-158
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Moderate to Severe Atopic Dermatitis
Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients
This is a randomized, double-blind, vehicle-controlled, parallel-group comparison study to evaluate the safety and efficacy of Q301 Cream vs. vehicle in adult subjects with moderate to severe AD.
- Trial name
- NCT02426359
- Testing
- Q301 Cream
- Where
- 7 sites in United States
- Volunteers
- 57 people
- Sponsor
- Qurient Co., Ltd.
Atopic Dermatitis
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body when used together with medicated creams or ointments in adults and adolescents with moderate to severe atopic…
- Trial name
- NCT07765888
- Testing
- Tilrekimig
- Where
- 21 sites in United States, Japan
- Volunteers
- 375 people
- Sponsor
- Pfizer
Moderate to Severe Atopic Dermatitis
A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis
This study is a multicenter, open-label, extended study to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of SHR-1819 injection in adult subjects with moderate to severe atopic dermatitis who have previously…
- Trial name
- NCT06012812
- Testing
- SHR-1819 injection
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Atopic Dermatitis
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children and adolescents (6 to <18 Years Old) with moderate atopic dermatitis.
- Trial name
- TRuE-AD5 (NCT06832618)
- Testing
- Ruxolitinib, Vehicle Cream
- Where
- 93 sites in United States, Belgium and 8 more
- Volunteers
- 159 people
- Sponsor
- Incyte Corporation
Children and Adolescents With Moderate-to-severe Atopic Dermatitis
A Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis
This trial was designed to evaluate the safety of SHR-1819 in children and adolescents with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06713499
- Testing
- SHR-1819 injection
- Where
- 2 sites in China
- Volunteers
- 51 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Dermatitis, Atopic
Study Of Atopic Dermatitis In Pediatrics
To verify of cetirizine dry syrup to ketotifen dry syrup in the change in the severity of pruritus of the treatment period.
- Trial name
- NCT00257569
- Testing
- Cetirizine Dry Syrup
- Volunteers
- 278 people
- Sponsor
- GlaxoSmithKline
Mild to Moderate Atopic Dermatitis
Observational Study to Evaluate Use of Elidel® in South and East Asian Pediatric Patients With Atopic Dermatitis.
Elidel® is indicated for the short-term treatment and long-term management of signs and symptoms of atopic dermatitis (AD) in infants (3 to 23 months), children (2 to 11 years), adolescents (12 to 17 years), and adults.
- Trial name
- Elidel-SEA (NCT06052995)
- Testing
- Elidel 1% Topical Cream
- Where
- 9 sites in Malaysia, Taiwan and 1 more
- Volunteers
- 130 people
- Sponsor
- BGP Products Operations GmbH, a Viatris company
Seborrhoeic Eczema of the Scalp
K301 for the Treatment of Seborrhoeic Eczema (SE) of the Scalp
Seborrhoeic eczema (SE) is a chronic, inflammatory skin disorder confined to areas of the head and trunk where sebaceous glands are most prominent.
- Trial name
- NCT01137331
- Testing
- K301
- Where
- 19 sites in Sweden
- Volunteers
- 201 people
- Sponsor
- Moberg Pharma AB
Atopic Dermatitis
Assessment of Pruritus Improvement With Pimecrolimus Treatment on the Areas Affected by Mild-to-moderate AD, in Patients 2- to 11- Year-old
The purpose of this study is to assess the efficacy and safety of pimecrolimus cream 1% in relation to the improvement of pruritus in pediatric patients (2- to 11- year-old) with mild to moderate atopic dermatitis.
- Trial name
- NCT00510003
- Testing
- Pimecrolimus
- Where
- Spain
- Volunteers
- 117 people
- Sponsor
- Novartis Pharmaceuticals
Eczema
Effectiveness of Clemastine Fumarate + Dexamethasone Compared to Dexchlorpheniramine Maleate in Eczema Treatment
Atopic dermatitis is a recurrent pruritic skin disorder which has a significant morbidity and impaired quality of life due specially pruritus and physical visible skin lesions.
- Trial name
- NCT01257061
- Testing
- Group 1, Group 2
- Where
- Brazil
- Volunteers
- 310 people
- Sponsor
- EMS
Atopic Dermatitis
Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis
The purpose of this study is to assess the safety and tolerability of repeated subcutaneous (SC) doses of Dupilumab in participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT01385657
- Testing
- Dupilumab, Background treatment
- Where
- 13 sites in Australia, Germany and 1 more
- Volunteers
- 37 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials
This is an Open-Label Extension (OLE) study to evaluate the long-term safety, tolerability, and efficacy of EDP1815 in participants with mild, moderate, and severe atopic dermatitis who have completed the treatment period of a…
- Trial name
- NCT05439941
- Testing
- EDP1815
- Where
- 54 sites in United States, Australia and 4 more
- Volunteers
- 287 people
- Sponsor
- Evelo Biosciences, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.